Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Radiopharmaceuticals (Strontium 89) and radiosensitizers (idoxuridine).

S E Otto1

  • 1Christi Regional Medical Center, Wichita, Kansas, USA.

Journal of Intravenous Nursing : the Official Publication of the Intravenous Nurses Society
|July 7, 1999
PubMed
Summary

Strontium 89 effectively alleviates pain from bone metastases in prostate and breast cancers. This radiopharmaceutical offers pain relief lasting weeks to months, administered intravenously in outpatient settings.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advanced concepts in chemotherapy drug delivery: regional therapy.

Journal of intravenous nursing : the official publication of the Intravenous Nurses Society·1995
Same author

Implementing guidelines for acute pain management.

Nursing management·1995
Same author

Nursing diagnosis: challenge for intravenous nursing practice.

Journal of intravenous nursing : the official publication of the Intravenous Nurses Society·1988
Same author

High pressure liquid chromatographic determination of sugars in various food products.

Journal - Association of Official Analytical Chemists·1979

Area of Science:

  • Oncology
  • Radiopharmaceuticals
  • Medical Physics

Background:

  • Bone metastases significantly impact patient quality of life.
  • Osteoblastic metastases from prostate and breast cancer are common.
  • Effective pain management for bone metastases remains a clinical challenge.

Purpose of the Study:

  • To evaluate the efficacy of Strontium 89 (Sr-89) in managing pain from osteoblastic bone metastases.
  • To review the mechanism of action for radiopharmaceuticals and radiosensitizers in cancer treatment.

Main Methods:

  • Intravenous administration of Strontium 89 (Sr-89) in an outpatient setting.
  • Review of clinical data on pain relief duration and onset.
  • Discussion of radiosensitizer mechanisms, including idoxuridine and hypoxic cell sensitizers.

Related Experiment Videos

Main Results:

  • Strontium 89 (Sr-89) provides significant pain relief for patients with bone metastases.
  • Pain relief onset is typically observed within 1-2 weeks.
  • The duration of pain relief can extend for several weeks to months.

Conclusions:

  • Strontium 89 (Sr-89) is an effective therapeutic option for pain palliation in patients with osteoblastic bone metastases.
  • Radiopharmaceuticals offer a targeted approach to pain management in advanced cancers.
  • Understanding radiosensitizer mechanisms may lead to improved combination therapies.